- £244.58m
- £229.08m
- £41.80m
- 69
- 16
- 76
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.71 | ||
| PEG Ratio (f) | 0.33 | ||
| EPS Growth (f) | 113.36% | ||
| Dividend Yield (f) | 1.96% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.73 | ||
| Price to Tang. Book | 6.47 | ||
| Price to Free Cashflow | 15.1 | ||
| Price to Sales | 5.85 | ||
| EV to EBITDA | 19.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.77% | ||
| Return on Equity | 4.37% | ||
| Operating Margin | 18.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 23.9 | 27.9 | 31.3 | 36.8 | 41.8 | 46.86 | 52.37 | 3.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +502.84 | -33.55 | -64.11 | +359.03 | -1.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Directors
- Ian Johnson CHM (67)
- Michael Roller CFO (55)
- Jonathan Emms COO
- Sarah Duncan SEC
- Nicholas Mills NED (30)
- Sharon Curran NID
- Joanna Le Couilliard NID (58)
- Garry Watts NID
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 19th, 2006
- Public Since
- March 13th, 2014
- No. of Employees
- 84
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 398,343,556
- Address
- Magdalen Centre, 1 Robert Robinson Ave, OXFORD, OX4 4GA
- Web
- https://investors.niox.com/
- Phone
- +44 1865405560
- Auditors
- RSM UK Audit LLP
Latest News for NIOX
Upcoming Events for NIOX
Niox Group PLC Annual Shareholders Meeting
Dividend For NIOX.L - 1.2500 GBX
Niox Group PLC Annual Shareholders Meeting
Half Year 2025 Niox Group PLC Earnings Release
Similar to NIOX
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 22:19 UTC, shares in Niox are trading at 61.40p. This share price information is delayed by 15 minutes.
Shares in Niox last closed at 61.40p and the price had moved by -9.17% over the past 365 days. In terms of relative price strength the Niox share price has underperformed the FTSE All Share Index by -11.66% over the past year.
The overall consensus recommendation for Niox is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Niox dividend yield is 2.04% based on the trailing twelve month period.
Last year, Niox paid a total dividend of £0.01, and it currently has a trailing dividend yield of 2.04%.Looking ahead, shares in Niox are due to go ex-dividend on 2025-05-15 and the next dividend pay date is 2025-06-16.
Niox are due to go ex-dividend on 2025-05-15 and the next dividend pay date is 2025-06-16. The historic dividend yield on Niox shares is currently 2.04%.
To buy shares in Niox you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 61.40p, shares in Niox had a market capitalisation of £244.58m.
Here are the trading details for Niox:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: NIOX
Based on an overall assessment of its quality, value and momentum Niox is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Niox is 79.75p. That is 29.89% above the last closing price of 61.40p.
Analysts covering Niox currently have a consensus Earnings Per Share (EPS) forecast of £0.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Niox. Over the past six months, its share price has underperformed the FTSE All Share Index by -1.44%.
As of the last closing price of 61.40p, shares in Niox were trading -4.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Niox PE ratio based on its reported earnings over the past 12 months is 17.71. The shares last closed at 61.40p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Niox's management team is headed by:
- Ian Johnson - CHM
- Michael Roller - CFO
- Jonathan Emms - COO
- Sarah Duncan - SEC
- Nicholas Mills - NED
- Sharon Curran - NID
- Joanna Le Couilliard - NID
- Garry Watts - NID